Evidence Explorer · MS-N250 · Mind–body and sleep · persistent insomnia after cancer · Appraised November 6, 2026
In cancer survivors with insomnia, the six-week OncoSleep web program with clinician support produced a large short-term improvement compared with a waitlist, with parallel improvements in fatigue and quality-of-life measures.
Evidence at a glance
- Benefit signal: Large short-term improvement in insomnia severity; supportive signals for fatigue and quality of life.
- Certainty: Moderate for short-term patient-reported insomnia versus waitlist; lower for durability and comparison with active care.
- Risk context: Low physical risk, but sleep restriction can transiently worsen sleepiness and needs tailoring for frailty, seizures, falls or safety-sensitive work.
- Cancer-control relevance: The study assessed symptoms and functioning, not recurrence or survival.
What was studied
The randomized trial assigned 154 adult cancer survivors with insomnia 1:1 to OncoSleep or a waitlist. The intervention used six weekly web modules with online clinician support.
The primary endpoint was insomnia severity after treatment; secondary outcomes included fatigue, cognitive functioning and physical and psychological quality of life.
What the study found
Mean insomnia change was −11.0 points with OncoSleep versus −1.4 with waitlist (p<.001; reported effect size d=−2.56).
Reported between-group effects also favored OncoSleep for fatigue (d=−1.35), cognitive functioning (d=0.95), physical quality of life (d=1.24) and psychological quality of life (d=0.80).
What this does not establish
A waitlist does not control for attention, expectancy or clinician contact. The eight-week assessment cannot establish long-term maintenance, and digital access and language requirements affect generalizability.
Large standardized effects in one trial should not be read as a guarantee for an individual survivor.
Safety and practical context
Digital CBT-I is not simply generic sleep advice: it uses stimulus control, sleep scheduling and cognitive strategies. A clinician should adapt sleep compression when there is severe daytime sleepiness, high fall risk, uncontrolled bipolar disorder, seizure risk or safety-critical employment.
Persistent snoring, witnessed apneas, restless legs or circadian problems may require a separate sleep evaluation.
Questions for the care team
- Is insomnia the main sleep disorder, or should apnea, restless legs, medication effects or mood symptoms be assessed first?
- Would clinician-supported web treatment be accessible and acceptable?
- How will daytime sleepiness and adherence be monitored?
Sources and identifiers
Funding and conflicts: Complete funding and conflict details were not fully verified beyond the accessible primary record.
Source access and dates: Primary abstract was appraised; full treatment-manual and adverse-event details were not independently verified. Sources checked November 6, 2026. Last literature search November 6, 2026.
Educational evidence summary, not individualized medical advice. Psychological and sleep interventions should complement—not replace—oncology, palliative, mental-health or sleep-medicine care.
